BioCentury | May 14, 2020
Management Tracks

Former GSK exec Slaoui to lead Trump’s ‘Warp Speed’ vaccine initiative

BIO President and CEO Jim Greenwood welcomed the appointment Wednesday of vaccine veteran Moncef Slaoui as head of the Trump administration’s Operation Warp Speed initiative, which is intended to fast-track COVID-19 vaccine development. Slaoui, now...
BC Extra | Sep 27, 2019
Politics & Policy

China unveils three-year plan for cancer prevention, control

China’s 2019-22 cancer prevention and control plan broadly outlines measures the country plans to take to standardize screening and treatment, improve access to cancer drugs and accelerate review of HPV vaccines. The plan, released Monday,...
BioCentury | Sep 7, 2017
Strategy

What if you build, but they don’t come

Vaccination is widely considered one of the greatest medical achievements of modern civilization. Diseases that were commonplace less than a generation ago, such as polio, smallpox and diphtheria, are now increasingly rare because of vaccines....
BioCentury | Oct 3, 2016
Finance

Dressed in black

Every single market cap band finished in the black in 3Q16, a feat not accomplished since the first quarter of 2014. M&A and a string of positive clinical and regulatory news fueled the 3Q16 rally...
BC Week In Review | Jul 25, 2016
Clinical News

Cervarix regulatory update

The China FDA approved Cervarix HPV vaccine from GlaxoSmithKline to prevent cervical cancer in women ages 9-25. GSK plans to launch the product in China in early 2017. The HPV types 16 and 18 vaccine...
BC Extra | Jul 18, 2016
Company News

China approves GSK's Cervarix

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said China FDA approved Cervarix to prevent cervical cancer. GSK said Cervarix is the first HPV vaccine approved in China. In early 2017, the company expects to launch the HPV types...
BC Week In Review | Jul 11, 2016
Clinical News

Cervarix regulatory update

EMA’s CHMP recommended expanding the label of Cervarix from GlaxoSmithKline to include prevention of premalignant anal lesions and anal cancers causally related to certain oncogenic HPV types in people ages >=9. The HPV types 16...
BC Innovations | Nov 19, 2015
Product R&D

Bugs against chlamydia

Synthetic biology company Prokarium Ltd. is creating oral vaccines based on a bacterial system that produces a wider range of antigens and fewer side effects than injectables. With its goal to produce the first vaccine...
BC Week In Review | Aug 17, 2015
Clinical News

Cervarix regulatory update

EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) began a safety review of human papillomavirus (HPV) vaccines, including Cervarix. PRAC will review rare reports of complex regional pain syndrome (CRPS) and postural orthostatic tachycardia syndrome to determine...
BC Innovations | Nov 13, 2014
Cover Story

Boosting adjuvants

For all the talk of new vaccines, not much attention has been paid to the need for better adjuvants, which have remained stuck on alum-based products for decades. The NIH is committing up to $70...
Items per page:
1 - 10 of 143